An Australian based medical device company, PolyNovo Limited (ASX:PNV) updated the market with its presentation to be presented at the Macquarie small and mid-cap virtual investor forum on 5 May 2020 and.
The Company discussed about its current products and first half outcomes in its investor’s presentation. The Current two products of the Company are- NovoSorb®BTM and NovoSorb® Syntrel.
The Cash on hand per March ASX announcement reported to be $7.4 million, and PNV received ascending revenues with the US in March.
Post announcement share price of PNV rose by 10.68% to $2.280 on 5 May 2020 (at AEST 12:18 AM).
Disclaimer
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.
